<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Peroxisome proliferator-activated receptors (PPARs) are therapeutic targets for fibrates and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, which are commonly used to ameliorate <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> and <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated whether activation of PPAR alpha and PPAR gamma stimulates neoangiogenesis </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We used selective synthetic PPAR alpha and PPAR gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> and investigated their angiogenic potentials in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Activation of PPAR alpha and PPAR gamma leads to endothelial tube formation in an endothelial/interstitial cell co-culture assay </plain></SENT>
<SENT sid="4" pm="."><plain>This effect is associated with increased production of the angiogenic cytokine vascular endothelial growth factor (VEGF) </plain></SENT>
<SENT sid="5" pm="."><plain>Neovascularization also occurs in vivo, when PPAR alpha and PPAR gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> are used in the murine corneal angiogenic model </plain></SENT>
<SENT sid="6" pm="."><plain>No vascular growth is detectable when PPAR alpha and PPAR gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> are respectively used in PPAR alpha knockout mice and mice treated with a specific PPAR gamma inhibitor, demonstrating that this angiogenic response is PPAR mediated </plain></SENT>
<SENT sid="7" pm="."><plain>PPAR alpha- and PPAR gamma-induced <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> is associated with local VEGF production and does not differ in extent and <z:mp ids='MP_0000002'>morphology</z:mp> from that induced by VEGF </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, PPAR alpha- and PPAR gamma-induced in vitro and in vivo <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> may be significantly decreased by inhibiting VEGF activity </plain></SENT>
<SENT sid="9" pm="."><plain>Finally, in corneas treated with PPAR alpha and PPAR gamma <z:chebi fb="4" ids="48705">agonists</z:chebi>, there is increased phosphorylation of endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase and Akt </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These findings demonstrate that PPAR alpha and PPAR gamma activation stimulates neoangiogenesis through a VEGF-dependent mechanism </plain></SENT>
<SENT sid="11" pm="."><plain>Neoangiogenesis is a crucial pathological event in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>The ability of PPAR alpha and PPAR gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> to induce neoangiogenesis might have important implications for the clinical and therapeutic management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>